Novo Nordisk Licenses Parkinson's Cell Therapy to AI Partner, Shutters Internal Unit
Novo Nordisk transferred its Parkinson's cell therapy program to AI-native firm Cellular Intelligence and closed the internal unit behind it. The move follows Q1 2026 results showing a 24.9% stock gain over 30 days. NVIDIA's BioNeMo platform, backed by deals with Eli Lilly and Thermo Fisher, is accelerating the shift toward outsourced, AI-driven drug development.
Salvado•